Aliskiren

證據等級: L5

預測適應症: 7 個

Using the drug-repurposing evaluation report template to convert this Evidence Pack into the required Markdown report. Note: this pack is a "multi" candidate file (7 predicted indications for aliskiren), so per the template's primary-indication rules I feature predicted_indications[0] in the Quick Overview/Title, and add one summary table covering all 7 candidates so the very different evidence quality across them (including a safety-relevant RCT signal) isn't lost.

Aliskiren: From Hypertension to Pulmonary Hypertension Due to Lung Disease/Hypoxia

One-Sentence Summary

Aliskiren is a direct renin inhibitor originally used to treat essential hypertension. The TxGNN model's top-ranked prediction is Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia, but this direction is currently supported only by 0 clinical trials and 20 publications, none of which specifically studied aliskiren, renin inhibition, or pulmonary hypertension. This Evidence Pack actually contains 7 predicted indications for aliskiren with widely varying evidence quality — from a mechanistically direct but untested hypothesis (renovascular hypertension) to a well-studied RCT signal that points toward harm rather than benefit (cerebrovascular disease, via the ALTITUDE trial).

Quick Overview

Item	Content
Original Indication	Hypertension (essential hypertension) — general drug-class knowledge; no formal licensing text is available since the product is not marketed in Germany in this dataset
Predicted New Indication	Pulmonary hypertension owing to lung disease and/or hypoxia
TxGNN Prediction Score	99.98% (rank 466 of full prediction list)
Evidence Level	L5
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Overview of All Predicted Indications in This Pack

This candidate pack (TW-DB09026-multi) contains 7 TxGNN-predicted indications for aliskiren. Evidence quality differs sharply between them and should be read together rather than in isolation:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommendation
1	Pulmonary hypertension owing to lung disease and/or hypoxia	99.98%	L5	S0	Hold
2	Pulmonary hypertension with unclear multifactorial mechanism	99.98%	L5	S0	Hold
3	Malignant hypertensive renal disease	99.98%	L4	S0	Hold
4	Malignant renovascular hypertension	99.98%	L3	S1	Research Question
5	Braddock syndrome	99.97%	L5	S0	Hold
6	Chronic pulmonary heart disease (cor pulmonale)	99.78%	L5	S0	Hold
7	Cerebrovascular disorder	99.19%	L1	S1	Hold — RCT evidence shows harm, not benefit

Note that the raw TxGNN score alone is not discriminating here — all 7 candidates score above 99%. The real differentiator is the evidence review below, especially rank 7, where the strongest clinical trial evidence in the entire pack (Phase 3 RCT, ALTITUDE) points against repurposing rather than for it.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for aliskiren is not available in this Evidence Pack (original_moa: [Data Gap]). Based on the literature captured in this pack (e.g., PMID 17485026, "Aliskiren, the first renin inhibitor for treating hypertension"), aliskiren is a first-in-class direct renin inhibitor: it blocks the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS), and its efficacy in essential hypertension is well established.

The 7 predicted indications above cluster around conditions in which RAAS overactivation is thought to play a role — renal, pulmonary vascular, and cerebrovascular pathology. The mechanistic plausibility, however, is far from uniform:

Most direct (rank 4, malignant renovascular hypertension): renal-artery-stenosis-driven hypertension is pathophysiologically defined by excess renin secretion from the underperfused kidney, so a renin inhibitor targets the upstream driver directly. The one supporting reference (PMID 17485026) is drug-specific but also warns that reactive renin secretion may blunt aliskiren's long-term antihypertensive effect in exactly this setting.
Plausible but indirect (rank 3, malignant hypertensive renal disease; rank 6, chronic pulmonary heart disease): RAAS activation is a recognized contributor to glomerular pressure injury and to right-heart volume overload, but the cited literature is not aliskiren-specific (a complement-pathway fibrosis study, and an ARNI heart-failure post-hoc analysis using a different drug class).
Weak/generic (ranks 1–2, hypoxia-driven pulmonary hypertension): hypoxia-induced pulmonary vascular remodeling does involve RAAS signaling in some preclinical reports, so the hypothesis is not implausible in principle. However, all 20 retrieved publications are general hypoxia-biology papers (neurodegeneration, cognition, tumor metabolism, high-altitude physiology) — none mention aliskiren, renin inhibitors, or pulmonary hypertension treatment, so this link is currently speculative rather than evidenced.
Likely noise (rank 5, Braddock syndrome): a CHARGE-like ciliopathy with no known RAAS/renin biology and zero supporting literature or trials — most plausibly a spurious knowledge-graph connection via a shared hypertension-comorbidity node.
Evidenced, but negative (rank 7, cerebrovascular disorder): this is the one candidate with genuine Phase 2/3 RCT data (ALTITUDE trial and its post-hoc analyses). The trial was terminated early because aliskiren, when combined with ACE inhibitors or ARBs in diabetic patients with renal impairment, increased rates of stroke, hypotension, and hyperkalemia rather than providing cerebrovascular protection — despite favorable preclinical (rodent) neuroprotection data.

Clinical Trial Evidence

Only two of the seven candidate indications have any registered trials.

Chronic pulmonary heart disease (rank 6):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03747107	N/A	Completed	19	Pharmacist-led, data-driven prescribing-safety QI program in primary care (Scotland). Grade C relevance — no direct link to aliskiren pharmacology or this indication; likely a low-relevance pipeline match.

Cerebrovascular disorder (rank 7):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01417104	Phase 2/3	Terminated	71	ALPINE trial: aliskiren vs. placebo for slowing atherosclerotic plaque progression in thoracic/abdominal aorta by MRI. Grade A relevance (drug- and mechanism-specific) but terminated well short of target enrollment — timing coincides with the 2011–2012 ALTITUDE safety signal that led Novartis to halt related aliskiren combination trials; termination reason should be verified directly.
NCT01454583	N/A	Completed	15,337	German 3A-Register: large real-world observational registry of RAS-inhibitor (including aliskiren) outpatient treatment patterns in hypertension. Grade B relevance — observational, not designed around cerebrovascular endpoints.

For pulmonary hypertension (ranks 1–2), malignant hypertensive renal disease (rank 3), malignant renovascular hypertension (rank 4), and Braddock syndrome (rank 5): currently no related clinical trials registered.

Literature Evidence

Cerebrovascular disorder (rank 7) — strongest and most drug-specific evidence in this pack

PMID	Year	Type	Journal	Key Findings
26523993	2015	RCT subgroup (ALTITUDE/AQUARIUS)	Atherosclerosis	Aliskiren's effect on coronary atheroma progression and MACE in diabetic vs. non-diabetic CAD patients; reinforces the diabetic-population harm signal.
23418282	2013	RCT post-hoc safety analysis	J Renin Angiotensin Aldosterone Syst	Hypotension and ischemic stroke associated with aliskiren in ALTITUDE, proposed mechanism via Bezold-Jarisch reflex sensitization.
26188211	2015	RCT post-hoc (ALTITUDE)	European Heart Journal	Mortality following a cardiovascular or renal event in T2DM patients in ALTITUDE — establishes the high-risk population where aliskiren + ACEi/ARB is harmful.
24621979	2013	Clinical review/analysis	JACC: Heart Failure	Examines whether dual RAAS blockade (including aliskiren combinations) is associated with increased stroke risk.
23541666	2013	Real-world database study	Canadian J Cardiology	Ontario administrative-data study found no increase in adverse events with aliskiren + ACEi/ARB in routine practice — offers a partially reassuring, contrasting real-world signal to the RCT findings.
40013543	2025	Cochrane systematic review/meta-analysis	Cochrane Database Syst Rev	Renin inhibitors vs. ARBs for primary hypertension — comparable BP-lowering, favorable tolerability, but not focused on cerebrovascular outcomes.
37439548	2023	Cochrane systematic review	Cochrane Database Syst Rev	First-line diuretics vs. other antihypertensive classes — general comparative-effectiveness context, not aliskiren-specific.
23541659	2013	Review	Canadian J Cardiology	Combination treatment with aliskiren and RAAS blockers — "reassurance but with a note of caution," commentary anticipating the ALTITUDE findings.
21859961	2011	Preclinical (mouse model)	Hypertension	Direct renin inhibition attenuated brain damage and cognitive impairment in chronic cerebral hypoperfusion mice — supportive mechanistic/preclinical signal, contradicted by later human RCT data.
27180190	2016	Preclinical (mouse model)	Neurochemical Research	Aliskiren showed neuroprotective effects (PI3K/AKT/Bcl-2 pathway) in experimental ischemic stroke — again preclinical only.

Pulmonary hypertension owing to lung disease and/or hypoxia (rank 1) — non-drug-specific hypoxia biology literature

PMID	Year	Type	Journal	Key Findings
33862277	2021	Review	Ageing Research Reviews	General review of hypoxia's role in brain aging and neurodegeneration; not aliskiren- or pulmonary-hypertension-specific.
34618295	2022	Review	Metabolic Brain Disease	Clinical and molecular mechanisms of hypoxia-induced cognitive impairment.
21328446	2011	Review	J Cellular Biochemistry	General hypoxia-mediated biological control across organ systems.
34535359	2021	Review	Clinical Oncology	Therapeutic modification of tumor hypoxia in oncology; unrelated to pulmonary vascular disease.
31706510	2019	Review	Trends in Cancer	Deubiquitinases and hypoxia signaling in cancer.
11172576	2000	Review	Respiratory Care Clinics of North America	Mechanisms of hypoxemia (ventilation-perfusion mismatch, shunt, etc.) — background respiratory physiology only.
40815459	2025	Review	Rev Med Inst Mex Seguro Soc	High-altitude hypobaric hypoxia and physiological adaptation.
40347693	2025	Review	Redox Biology	Hypoxia's role in multiple sclerosis pathology.
37328448	2023	Preclinical	Advanced Science	ac4C/NAT10/HIF-1α feedback loop driving glycolysis in gastric cancer under hypoxia.
24557798	2014	Editorial	J Applied Physiology	Brief editorial framing on hypoxia research ("translation in progress"); no abstract available.

None of these 10 (or the remaining 10 in the full retrieval set) discuss aliskiren, renin inhibition, or pulmonary hypertension treatment. This is the key limitation behind the L5/Hold rating for rank 1–2.

Malignant hypertensive renal disease (rank 3)

PMID	Year	Type	Journal	Key Findings
37919077	2023	Preclinical (mechanism study)	Frontiers in Bioscience	C3aR antagonism restores mitochondrial fatty-acid oxidation and reduces tubular profibrotic changes in renin-dependent hypertension — a complement-pathway mechanism study, not an aliskiren efficacy study.

Malignant renovascular hypertension (rank 4)

PMID	Year	Type	Journal	Key Findings
17485026	2007	Drug-specific pharmacology review	American Journal of Hypertension	Review of 6 clinical trials (>5,000 patients) — aliskiren is no more effective than ACEi/ARB/diuretics for BP lowering; warns that reactive renin secretion may limit long-term effectiveness, directly relevant to the renovascular-hypertension hypothesis.

Chronic pulmonary heart disease (rank 6)

PMID	Year	Type	Journal	Key Findings
39210725	2024	RCT post-hoc	JAMA Cardiology	Sacubitril/valsartan (ARNI — a different drug class) effect on all-cause hospitalization in heart failure (PARADIGM-HF/PARAGON-HF); not a renin-inhibitor study.
17890152	2007	Conference review	European Journal of Heart Failure	ESC 2007 heart-failure trial roundup (3CPO, ALOFT, PROSPECT, statins); general background only.

Germany Market Information

Aliskiren is currently not marketed in Germany according to this dataset (market_status: 未上市, total_licenses: 0). No marketing authorization records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information — the structured safety fields in this Evidence Pack (key_warnings, contraindications, ddi) are all marked as data gaps, and the TFDA/BfArM package insert has not yet been retrieved (see DG001, Blocking).

⚠️ Important safety signal identified from literature evidence (not from the formal safety data fields above): Multiple publications retrieved for the cerebrovascular-disorder candidate (rank 7) reference the ALTITUDE trial, a Phase 3 RCT that was terminated early because aliskiren, when combined with an ACE inhibitor or ARB in patients with type 2 diabetes and renal impairment, significantly increased rates of stroke, hypotension, and hyperkalemia (PMID 23418282, 26188211, 26523993). This is a well-documented, drug-specific harm signal and should be treated as a hard constraint on any repurposing work involving renal or cardiovascular comorbidity populations until the formal package insert warnings are retrieved and reviewed.

Conclusion and Next Steps

Decision: Hold (top-ranked candidate, and program-level default pending further data)

Rationale:

The featured top prediction (pulmonary hypertension owing to lung disease/hypoxia) has no aliskiren-specific clinical trial or literature support (L5) — the TxGNN score alone is not sufficient to advance it.
Across all 7 candidates in this pack, only malignant renovascular hypertension (rank 4) has a mechanistically direct, drug-specific rationale and is rated Research Question rather than Hold — but even there, the literature itself cautions that reactive renin secretion may limit aliskiren's effectiveness.
The candidate with the strongest clinical evidence, cerebrovascular disorder (rank 7, L1), should not be pursued: its Phase 3 RCT evidence (ALTITUDE) shows increased stroke and renal harm in the relevant patient population, not benefit.
A Blocking data gap exists (DG001): TFDA/BfArM package insert warnings and contraindications have not been retrieved, so no candidate can proceed past initial safety screening (S1) regardless of efficacy evidence.

To proceed, the following is needed:

Retrieve and parse the TFDA/BfArM package insert (warnings, contraindications) — currently Blocking (DG001)
Obtain confirmed mechanism-of-action data from DrugBank (DG002) to firm up the mechanistic rationale sections above
If pursuing rank 4 (malignant renovascular hypertension) as a Research Question, commission a targeted literature/trial search specific to that indication (current evidence base is a single 2007 review)
Verify the termination reason for NCT01417104 (ALPINE) to confirm whether it relates to the ALTITUDE safety signal
Treat rank 7 (cerebrovascular disorder) as closed/Do-Not-Pursue pending any new evidence that overturns the ALTITUDE findings
Disregard rank 2 (no evidence) and rank 5 (Braddock syndrome, biologically implausible) as likely knowledge-graph noise unless new evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.